Sugi Predict

Sugi Predict / Compounds / SCHEMBL574989

SCHEMBL574989

SCHEMBL574989

CCOC(=O)c1cnc(Cl)c([N+](=O)[O-])c1Cl

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.49
▸ KMT2A Q03164 4/20 0.47
▸ MEN1 O00255 3/20 0.46
▸ MAPT P10636 4/20 0.44
▸ KDM4E B2RXH2 5/20 0.43
▸ NPC1 O15118 3/20 0.42
▸ RAB9A P51151 3/20 0.42
▸ POLB P06746 2/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ HPGD P15428 3/20 0.41
▸ HSP90AA1 P07900 2/20 0.41
▸ GALR2 O43603 1/20 0.41
▸ MITF O75030 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ XBP1 P17861 1/20 0.41
▸ CCR6 P51684 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ GAA P10253 1/20 0.40
▸ MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30846439 1.00 ALDH1A1 (0.49) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL27314724 0.89 ALDH1A1 (0.49) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL4497497 0.86 ALDH1A1 (0.47) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL14031475 0.86 ALDH1A1 (0.47) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL3216900 0.85 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL14468617 0.84 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL14543449 0.84 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL4766494 0.84 ALDH1A1 (0.46) ALDH1A1KMT2AMEN1MAPTKDM4E
SCHEMBL4718816 0.84 SMN1; SMN2 (0.41) ALDH1A1KMT2AMEN1MAPTPOLB
SCHEMBL24455485 0.83 ALDH1A1 (0.45) ALDH1A1KMT2AMEN1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025236100-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2025-11-20 — — WO disclosed
US-12421230-B2 Tricyclic heteroaryl compounds useful as IRAK4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2025-09-23 — — US disclosed
EP-4577536-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY Hotspot Therapeutics, Inc. (US) 2025-07-02 — — EP disclosed
US-20240279233-A1 MACROCYCLIC TAK1 INHIBITORS AQILION AB (SE) 2024-08-22 — — US disclosed
CN-115335380-B Tricyclic heteroaryl compounds useful as IRAK4 inhibitors 百时美施贵宝公司 2024-08-02 — — CN disclosed
US-20240150365-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. 2024-05-09 — — US disclosed
US-20240150321-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. 2024-05-09 — — US disclosed
EP-4363422-A1 MACROCYCLIC TAK1 INHIBITORS Aqilion AB (SE) 2024-05-08 — — EP disclosed
WO-2024044730-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed
WO-2024044344-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed
US-20080255143-A1 Inhibitors of Akt Activity SMITHKLINE BEECHAM CORPORATION (PA) 2008-10-16 — — US disclosed
WO-2008116816-A1 COMBINATION OF CB2 LIGAND AND PARACETAMOL GLAXO GROUP LIMITED (GB) 2008-10-02 — — WO disclosed
US-20080221097-A1 Imidazopyridine Derivatives as Cannabinoid Receptor Ligands GLAXO GROUP LIMITED 2008-09-11 — — US disclosed
EP-1912985-A1 IMIDAZOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2008-04-23 — — EP disclosed
WO-2008017696-A1 NEW MACROLIDES USEFUL AGAINST INFLAMMATORY AND ALLERGIC DISSEASES BASILEA PHARMACEUTICA AG (CH) 2008-02-14 — — WO disclosed
US-20070155777-A1 Antiinflammation agents AMGEN, INC. 2007-07-05 — — US disclosed
US-7199119-B2 Antiinflammation agents AMGEN INC. (US) 2007-04-03 — — US disclosed
WO-2007017237-A1 IMIDAZOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2007-02-15 — — WO disclosed
EP-1653961-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2006-05-10 — — EP disclosed
WO-2005011700-A1 INHIBITORS OF Akt ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2005-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150321-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL3 ALDH1A1 3268/4885KMT2A 1246/4885MEN1 1694/4885
US-20080255143-A1 Inhibitors of Akt Activity PI4KB, PIK3CA, AKT2 ALDH1A1 4166/4885KMT2A 1852/4885MEN1 3151/4885
US-20070155777-A1 Antiinflammation agents TNF, NFATC1, NFKBIA ALDH1A1 3037/4885KMT2A 4609/4885MEN1 4619/4885
US-20240150365-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL6B ALDH1A1 3059/4885KMT2A 974/4885MEN1 924/4885
US-12421230-B2 Tricyclic heteroaryl compounds useful as IRAK4 inhibitors IRAK4, IRAK3, IRAK2 ALDH1A1 3424/4885KMT2A 283/4885MEN1 2421/4885
US-20080221097-A1 Imidazopyridine Derivatives as Cannabinoid Receptor Ligands CNR1, CNR2, TRPV1 ALDH1A1 3269/4885KMT2A 2837/4885MEN1 4644/4885
US-20240279233-A1 MACROCYCLIC TAK1 INHIBITORS TAB1, TBK1, IRAK3 ALDH1A1 4416/4885KMT2A 1921/4885MEN1 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.